Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Symptoms in Borderline Personality Disorder
NCT06759298Phase 1Not yet recruiting
- Sponsor
- Tanta University
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in borderline personality disorder (BPD) comparing Concerta Group with Placebo Group (2 arms). Primary endpoints: Reduction in impulsivity and mood instability at 3 months, Reduction of depression symptoms at 3 months and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT06759298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759298.